J. Robson

发表

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process

P. Tugwell, J. Krischer, J. Farrar, 2015, The Journal of Rheumatology.

J. Farrar, P. Merkel, J. Dawson, 2018, Patient related outcome measures.

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

H. Doll, P. Höglund, J. Robson, 2015, Annals of the rheumatic diseases.

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.

H. Doll, P. Höglund, J. Robson, 2015, Rheumatology.

ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives

J. Robson, S. McAdoo, K. Austin, 2022, Journal of inflammation research.

The Patients' Perspective of Important Glucocorticoid Effects

J. Singh, S. Goodman, C. Hill, 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

The patient perspective of nurse-led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis.

J. Robson, P. Richards, C. Flurey, 2020, Journal of clinical nursing.

Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018

P. Tugwell, P. Merkel, C. Hill, 2015, The Journal of Rheumatology.

Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

P. Merkel, S. Mackie, G. Hatemi, 2015, The Journal of Rheumatology.

Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2020, Arthritis care & research.

Introduction, epidemiology and classification of vasculitis.

J. Robson, R. Watts, 2018, Best practice & research. Clinical rheumatology.

Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016

P. Merkel, J. Robson, N. Milman, 2017, The Journal of Rheumatology.

The association of vascular risk factors with visual loss in giant cell arteritis

P. Merkel, J. Robson, R. Luqmani, 2016, Rheumatology.

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis

P. Merkel, J. Dawson, J. Shea, 2017, Rheumatology International.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

Long-Term Outcome of ANCA-Associated Systemic Vasculitis

J. Robson, T. Reynolds, J. Ritchie, 2016 .

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?

P. Merkel, A. Judge, J. Robson, 2017, Rheumatology.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis

P. Tugwell, J. Farrar, P. Merkel, 2017, The Journal of Rheumatology.

The Journal of Rheumatology associated Vasculitis − Antineutrophil Cytoplasmic Antibody OMERACT Endorsement of Patient-reported Outcome Instruments in

P. Tugwell, J. Farrar, P. Merkel, 2017 .

Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort

P. Merkel, J. Robson, R. Luqmani, 2019, Arthritis & rheumatology.

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS)

P. Merkel, A. Judge, J. Robson, 2013, Clinical and Experimental Nephrology.

The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future

P. Tugwell, R. Black, J. Robson, 2019, The Journal of Rheumatology.

Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group

R. Black, S. Goodman, C. Hill, 2019, The Journal of Rheumatology.

P185 Patient perceptions of physical activity following a diagnosis of giant cell arteritis: a multinational qualitative study

C. Hill, S. Mackie, J. Robson, 2020, Rheumatology.

Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health

P. Tugwell, P. Merkel, A. Boonen, 2019, The Journal of Rheumatology.

The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group.

R. Black, S. Goodman, C. Hill, 2020, Seminars in arthritis and rheumatism.

A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group

R. Black, S. Goodman, C. Hill, 2017, The Journal of Rheumatology.

FRI0464 Development of the Classification Criteria for GIANT Cell Arteritis in the Diagnostic and Classification Criteria for Vasculitis Study: A Pilot Study Using A Panel Review Methodology

A. Judge, J. Robson, R. Luqmani, 2014 .

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

P. Merkel, J. Stone, P. Bekker, 2022, Seminars in Arthritis & Rheumatism.

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

D. T. Gray, Janet A. Blood, I. Bruce, 2020, Rheumatology.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

D. D'cruz, N. Basu, A. Salama, 2020, Rheumatology.

Early development of new cardiovascular risk factors in the systemic vasculitides.

P. Merkel, C. Klersy, C. Montecucco, 2019, Clinical and experimental rheumatology.

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative Data

S. Mackie, J. Robson, E. Hoon, 2021, Arthritis care & research.

2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis

P. Merkel, A. Judge, J. Robson, 2022, Annals of the Rheumatic Diseases.

2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

R. Domsic, A. Herrick, L. Saketkoo, 2018, Arthritis care & research.

Patient reported outcomes in systemic vasculitis

J. Robson, K. Austin, M. Wells, 2021, Current opinion in rheumatology.

Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire

P. Merkel, H. Doll, J. Dawson, 2018, Annals of the rheumatic diseases.

Pulmonary Involvement in Primary Systemic Vasculitides.

P. Merkel, J. Robson, R. Luqmani, 2021, Rheumatology.

Patient Reported Outcomes in Large Vessel Vasculitides

C. Hill, S. Mackie, J. Robson, 2021, Current Rheumatology Reports.

1 VALIDATION OF THE ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOMES ( AAV-PRO ) QUESTIONNAIRE 1

J. Dawson, J. Robson, 2018 .

Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals’ perspectives

J. Robson, M. Shepherd, C. Flurey, 2020, Rheumatology advances in practice.

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

N. Arden, A. Kiran, J. Robson, 2015, Annals of the rheumatic diseases.

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis

L. Coates, I. Vlaev, S. Shepperd, 2020, Annals of the Rheumatic Diseases.

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study

N. Arden, A. Kiran, J. Robson, 2016, The Journal of Rheumatology.

Treat-to-target in PsA: methods and necessity

L. Coates, I. Vlaev, S. Shepperd, 2020, RMD Open.

Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study

M. Boers, S. Goodman, C. Hill, 2020, The Journal of Rheumatology.

a repository copy of Feasibility and face validity of outcome measures for use in future studies of Polymyalgia Rheumatica (PMR): An OMERACT Study

Maarten, S. Goodman, B. Shea, 2021 .

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]

J. Robson, S. McAdoo, K. Austin, 2022, Journal of inflammation research.

Patient-reported outcomes in vasculitis.

J. Robson, K. Austin, H. Crawshaw, 2023, Best practice & research. Clinical rheumatology.

OP0021 Draft classification criteria for the anca associated vasculitides

P. Merkel, J. Barrett, A. Judge, 2018, WEDNESDAY, 13 JUNE 2018.

2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis

P. Merkel, A. Judge, J. Robson, 2022, Arthritis & rheumatology.

Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure

J. Dawson, C. Hill, S. Mackie, 2021, Rheumatology.

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

H. Doll, P. Höglund, J. Robson, 2012 .

FRI0707-HPR IS A TAILORED DELIVERY OF NORDIC WALKING ACCEPTABLE FOR PEOPLE WITH INFLAMMATORY RHEUMATIC DISEASE?

R. Greenwood, J. Robson, F. Cramp, 2019, HPR Interventions (educational, physical, social and psychological).

P. Merkel, J. Robson, N. Milman, 2018, Clinical and experimental rheumatology.

Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes

P. Merkel, J. Dawson, J. Robson, 2019, Patient related outcome measures.

Outcome measures in ANCA-associated vasculitis.

J. Robson, R. Luqmani, R. Suppiah, 2010, Rheumatic diseases clinics of North America.

Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis

J. Farrar, P. Merkel, L. Moreland, 2019, The Journal of Rheumatology.

The global burden of anti-neutrophil cytoplasmic antibody vasculitis: High but unquantified.

J. Robson, R. Watts, F. Pearce, 2016, Rheumatology.

083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS

P. Merkel, L. Moreland, K. Maksimowicz-McKinnon, 2019, Rheumatology.

077. CLASSIFICATION CRITERIA FOR LARGE-VESSEL VASCULITIS

P. Merkel, A. Judge, J. Robson, 2019, Rheumatology.

AB0834 DEVELOPMENT OF A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOME MEASURE TO CAPTURE PATIENTS’ PERCEPTIONS OF GLUCOCORTICOID THERAPY DURING TREATMENT FOR RHEUMATIC DISEASES

R. Black, S. Goodman, S. Mackie, 2021 .

Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.

Win Min Oo, P. Tugwell, M. Petri, 2021, Seminars in arthritis and rheumatism.

Current Status of Outcome Measure Development in Vasculitis

P. Merkel, M. Boers, E. Matteson, 2014, The Journal of Rheumatology.

Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure

R. Black, J. Dawson, S. Goodman, 2023, Rheumatology.

AB0607 SELF-MANAGEMENT BEHAVIOURS IN ANCA-ASSOCIATED VASCULITIS: SECONDARY ANALYSIS OF INTERVIEW DATA

J. Robson, N. Milman, P. Cronholm, 2019, Abstracts accepted for Publication.

Validation of a patient-reported outcome measure for giant cell arteritis

J. Dawson, S. Mackie, J. Robson, 2023, Rheumatology.

Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study

N. Arden, A. Kiran, J. Robson, 2016, The Journal of Rheumatology.

The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

N. Arden, A. Kiran, J. Robson, 2013 .

SAT0216 PATIENT PERCEPTIONS OF PHYSICAL ACTIVITY AFTER A DIAGNOSIS OF GIANT CELL ARTERITIS: A SECONDARY ANALYSIS OF MULTINATIONAL QUALITATIVE DATA

C. Hill, S. Mackie, J. Robson, 2019, Saturday, 15 June 2019.

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis

R. Domsic, A. Herrick, L. Saketkoo, 2018, Arthritis care & research.

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

F. Pieruzzi, B. Rovin, V. Strand, 2023, The Lancet. Rheumatology.

Assessing glucocorticoid toxicity: are the measures sensitive enough?

J. Robson, J. Dawson, Mwidimi Ndosi, 2023, The Lancet Rheumatology.